Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Griffen EJ., Fearon D., McGovern BL., Koekemoer L., Balcomb BH., Szommer T., Fate G., Robinson RP., Lefker BA., Duberstein S., Lahav N., Braillard S., Vangeel L., Laporte M., Charvillon FB., MacLeod AK., Wells A., Garner P., Knight R., Rees P., Simon A., Jochmans D., Neyts J., Read KD., Barr H., Robinson M., Lee A., London N., Chodera J., von Delft F., White KM., Perry B., Sjö P., von Delft A.

DOI

10.1101/2025.06.16.660018

Type

Preprint

Publication Date

2025-06-17T00:00:00+00:00

Permalink More information Close